1349644-17-2

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-Boc-3-allylpiperidine-3-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures. Its reactivity and versatility make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 1-Boc-3-allylpiperidine-3-carboxylate is utilized as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its role as a building block allows for the development of innovative and effective products to protect crops and enhance agricultural productivity.
Safety Precautions:
It is crucial to handle Methyl 1-Boc-3-allylpiperidine-3-carboxylate with care, as it can be hazardous if not properly managed. Adequate safety measures should be taken during its production, storage, and use to minimize potential risks and ensure the well-being of individuals involved in its application.

Upstream product

• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 106-95-6 allyl bromide 
• 148763-41-1 1-(tert-butyl) 3-methyl piperidine-1,3-dicarboxylate 

Downstream Products

• 374795-33-2 (RS)-1,1-dimethylethyl 2-oxa-1-oxo-7-azaspiro[4,5]decan-7-carboxylate 
• 1349643-97-5 7-{[4-(trifluoromethyl)phenyl]sulfonyl}-2-oxa-7-azaspiro[4.5]decan-1-one 
• 1349643-99-7 7-({4-[(trifluoromethyl)oxy]phenyl}sulfonyl)-2-oxa-7-azaspiro[4.5]decan-1-one 

Relevant academic research and scientific papers

RAS INHIBITORS

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS

The invention relates to novel spirocyclic derivatives with affinity for Cav2.2 calcium channels and which are capable of interfering with Cav2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy for the treatment of pain.

Synthesis and structure-activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors

Replacement of the amide functionality in IM491 (N-hydroxy-(5S,6S)-1- methyl-6-{[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl} -5-piperidinecarboxamide) with a sulfonyl group led to a new series of α,β-cyclic and β,β-cyclic γ-sulfonyl hydroxamic acids, which were potent TNF-α converting enzyme (TACE) inhibitors. Among them, inhibitor 4b (N-hydroxy-(4S,5S)-1-methyl-5-{[4-(2-methyl-4- quinolinylmethoxy)phenyl]sulfonylmethyl}-4-pyrrolidinecarboxamide) exhibited IC50 values of 1 nM and 180 nM in porcine TACE (pTACE) and cell assays, respectively, with excellent selectivity over MMP-1, -2, -9 and -13 and was orally bioavailable with an F value of 46% in mice.